Table 4.
Multiple linear regression analyses examining predictors of neurocognitive performance and functional impairment in the older study groups (OH-MA-, OH+MA-, OH+MA+).
| Adj R2 | F | Estimate | 95% CI | p-value | |
|---|---|---|---|---|---|
| Global T-Score | 0.15 | 4.27 | ----- | ----- | <0.001 |
| HIV/MA Risk Groupa | ----- | ----- | ----- | ||
| H+MA- | −2.14 | −4.87, 0.58 | 0.122 | ||
| H+MA+ | −6.22 | −9.40, −3.04 | <0.001 | ||
| Comorbidity Rating [contributing] | −2.28 | −4.62, 0.06 | 0.056 | ||
| Affective Diagnoses [yes] | 0.22 | −2.15, 2.58 | 0.857 | ||
| LT Non-MA Substance Abuse [yes] | 2.70 | 0.18, 5.22 | 0.036 | ||
| UDS Status [positive] | −1.25 | −3.96, 1.46 | 0.362 | ||
| Learning T Score | 0.14 | 4.12 | ----- | ----- | <0.001 |
| HIV/MA Risk Groupa | ----- | ----- | ----- | ||
| H+MA- | −1.83 | −6.23, 2.57 | 0.411 | ||
| H+MA+ | −9.17 | −14.31, −4.04 | <0.001 | ||
| Comorbidity Rating [contributing] | −4.25 | −8.03, −0.47 | 0.028 | ||
| Affective Diagnoses [yes] | 0.58 | −3.24, 4.39 | 0.765 | ||
| LT Non-MA Substance Abuse [yes] | 2.08 | −1.99, 6.15 | 0.314 | ||
| UDS Status [positive] | −1.16 | −5.34, 3.21 | 0.599 | ||
| Memory T Score | 0.12 | 3.52 | ----- | ----- | 0.003 |
| HIV/MA Risk Groupa | ----- | ----- | ----- | ||
| H+MA- | −2.08 | −6.24, 2.09 | 0.325 | ||
| H+MA+ | −7.86 | −12.73, −3.00 | 0.002 | ||
| Comorbidity Rating [contributing] | −3.79 | −7.37, −0.20 | 0.038 | ||
| Affective Diagnoses [yes] | 1.15 | −2.47, 4.76 | 0.531 | ||
| LT Non-MA Substance Abuse [yes] | 1.03 | −2.82, 4.89 | 0.596 | ||
| UDS Status [positive] | −2.03 | −6.17, 2.11 | 0.333 | ||
| Attention T Score | 0.15 | 4.26 | ----- | ----- | <0.001 |
| HIV/MA Risk Groupa | ----- | ----- | ----- | ||
| H+MA- | −4.36 | −8.38, −0.34 | 0.034 | ||
| H+MA+ | −9.05 | −13.75, −4.36 | <0.001 | ||
| Comorbidity Rating [contributing] | −3.37 | −6.83, 0.09 | 0.056 | ||
| Affective Diagnoses [yes] | 1.28 | −2.21, 4.77 | 0.469 | ||
| LT Non-MA Substance Abuse [yes] | 5.09 | 1.37, 8.81 | 0.008 | ||
| UDS Status [positive] | −0.24 | −4.24, 3.76 | 0.905 | ||
| Executive Functions T Score | 0.06 | 2.19 | ----- | ----- | 0.049 |
| HIV/MA Risk Groupa | |||||
| H+MA- | −1.97 | −5.60, 1.67 | 0.286 | ||
| H+MA+ | −5.75 | −9.99, −1.51 | 0.008 | ||
| Comorbidity Rating [contributing] | 0.03 | −3.10, 3.15 | 0.986 | ||
| Affective Diagnoses [yes] | −0.03 | −3.19, 3.12 | 0.983 | ||
| LT Non-MA Substance Abuse [yes] | 4.75 | 1.39, 8.11 | 0.006 | ||
| UDS Status [positive] | −2.92 | −6.53, 0.69 | 0.112 | ||
| SIP T Score | 0.01 | 0.81 | ----- | ----- | 0.563 |
| HIV/MA Risk Groupa | ----- | ----- | ----- | ||
| H+MA- | −0.85 | −4.63, 2.94 | 0.658 | ||
| H+MA+ | −0.90 | −5.32, 3.52 | 0.687 | ||
| Comorbidity Rating [contributing] | −0.11 | −3.36, 3.15 | 0.948 | ||
| Affective Diagnoses [yes] | −0.08 | −3.36, 3.21 | 0.964 | ||
| LT Substance Abuse [yes] | 2.21 | −1.29, 5.71 | 0.214 | ||
| UDS Status [positive] | −3.14 | −6.90, 0.63 | 0.101 | ||
| Motor T Score | 0.06 | 2.28 | ----- | ----- | 0.041 |
| HIV/MA Risk Groupa | ----- | ----- | ----- | ||
| H+MA- | −0.77 | −5.30, 3.75 | 0.735 | ||
| H+MA+ | −3.40 | −8.68, 1.88 | 0.205 | ||
| Comorbidity Rating [contributing] | −3.77 | −7.64, 0.11 | 0.057 | ||
| Affective Diagnoses [yes] | −1.05 | −4.97, 2.87 | 0.598 | ||
| LT Substance Abuse [yes] | −1.56 | −5.74, 2.61 | 0.460 | ||
| UDS Status [positive] | −2.01 | −6.50, 2.48 | 0.376 |
a
Note. Reference group is H-MA-.
LT = Lifetime. UDS = Urine drug screen. SIP = Speed of information processing.